News + Font Resize -

HCL enters into partnership with Visiprise
Our Bureau, New Delhi | Wednesday, January 23, 2008, 08:00 Hrs  [IST]

HCL Technologies Ltd (HCL), a leading global IT services company, has entered into a global consulting partnership with Visiprise, Inc for the life sciences industry, covering all aspects of the medical device manufacturing cycle.

The consulting agreement will include joint marketing, sales and pre-sales services and will result in the ability for seamless licensing, blueprinting, implementation, plant-business integration, roll-out, support, upgrade / migration and instance consolidation services to manufacturers, a release said. Under this agreement, Visiprise will also be training and certifying HCL consultants on Visiprise solutions.

Speaking on the occasion Pradeep Nair, VP, global life sciences and healthcare practice, HCL Technologies said, "HCL's partnership with Visiprise is well poised in bringing about the transformational change in plant operations. We believe that Visiprise's technology and strategic alignment with SAP and PLM vendors will help customers in seamless business integration from shop-floor to top-floor, which aligns well with HCL's focus towards manufacturing IT solutions and services''.

"HCL's focus in medical devices, coupled with their comprehensive approach in providing total plant-level IT aligns well with our vision of delivering a total manufacturing solution for the integrated enterprise," said Mike Lacky, vice president of industry business units from Visiprise.

Visiprise is a leading provider of manufacturing execution for integrated manufacturing operations. The Life Sciences & Healthcare practice at HCL delivers IT centric solutions across the pharmaceutical, medical device and hospital industries. HCL continues to invest in providing tested solutions in arenas such as Pharmacogenomics, medical devices and diagnostics, contract manufacturing, and hospital information systems. The Life Sciences & Healthcare team comprises 1500 consultants, including regulatory experts, bio technologists and pharmaceutical industry experts.

Post Your Comment

 

Enquiry Form